Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Hangzhou Tianlong Pharmaceutical Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct examiners and 2 distinct art units, indicating a fragmented prosecution landscape despite the small volume of active matters. The presence of 2 distinct art units suggests that the company's intellectual property covers diverse technical aspects within the broader pharmaceutical sector.
HUDSON, AMY ROSE is identified as the busiest examiner for this portfolio, currently overseeing 1 pending office action. This represents 1 of the 2 total pending office actions for the company. Because the 2 pending office actions are split between 2 distinct examiners, the prosecution strategy must account for the individual tendencies of different officials rather than a centralized review process. Practitioners should monitor the 2 distinct art units to ensure consistency in arguments across the different examination groups.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEBB, WALTER E | 1 | 46.3% | +18.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18997401 | CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY, LOW TOXICITY AND STABLE EXPRESSION, AND COMPOSITION COMPRISNG SAME | WEBB, WALTER E | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18997401 | CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY, LOW TOXICITY AND STABLE EXPRESSION, AND COMPOSITION COMPRISNG SAME | WEBB, WALTER E | 1612 | §103 | Non-Final OA | — | Pending | Jan 21, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHangzhou Tianlong Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Walter E Webb has the most, with 1 of Hangzhou Tianlong Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
